<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286780</url>
  </required_header>
  <id_info>
    <org_study_id>AT-101-CS-008</org_study_id>
    <nct_id>NCT00286780</nct_id>
  </id_info>
  <brief_title>Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 2, Open Label Study of AT-101 in Combination With Rituximab in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascenta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascenta Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in
      combination with rituximab in patients with relapsed or refractory chronic lymphocytic
      leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of AT-101 in combination with rituximab</measure>
    <time_frame>5 months for each patient; 20 months entire study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of AT-101 in combination with rituximab</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-101</intervention_name>
    <description>80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CLL as defined by the NCI-working group

          -  Previous treatment with standard systemic chemotherapy or immunotherapy.

          -  Disease progression or relapse after treatment.

          -  Indication for treatment as defined by the NCI Working Group Guidelines (Cheson, 1996)

          -  ECOG performance status ≤ 2

          -  Adequate liver and renal and bone marrow function

        Exclusion Criteria:

          -  Treatment of CLL with chemotherapy, monoclonal antibody or radiotherapy within 60 days
             prior to entering the study. Acute toxicities from prior therapy must have resolved to
             Grade ≤ 1.

          -  Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional
             Classification

          -  Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of
             breath, COPD)

          -  Active secondary malignancy or history of other malignancy within the last five years

          -  Active symptomatic fungal, bacterial and/or viral infection including active HIV or
             viral hepatitis (A, B or C).

          -  Patients who are contraindicated for treatment with rituximab

          -  Diagnosis of prolymphocytic leukemia, hairy cell leukemia, leukemic phase of
             non-Hodgkin's lymphoma, or other non-B-CLL B-cell malignancy;

          -  T-CLL or other T-cell malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kipps, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <last_update_submitted>August 12, 2010</last_update_submitted>
  <last_update_submitted_qc>August 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Brian Wood, Associate Director, Clinical Development</name_title>
    <organization>Ascenta Therapeutics</organization>
  </responsible_party>
  <keyword>AT101</keyword>
  <keyword>AT-101</keyword>
  <keyword>cancer</keyword>
  <keyword>lymphoctic</keyword>
  <keyword>lukemia</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gossypol acetic acid</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Gossypol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

